CereCRIB implant: Phase I extension trial

CytoTherapeutics Inc. (CTII), Princeton, N.J. Product: CereCRIB implant Indication: Treat chronic, intractable pain associated with cancer Status: Started an elevated dose, Phase I extension trial of...